Thank you for subscribing!
Learn More about Next Investors - Experts in Biotech Stocks
Next Investors Archived Dec 03, 2019
Through partnerships with leading global companies, Creso Pharma (ASX:CPH) has been able to, and will continue to accelerate the development and distribution of its products worldwide.
Next Investors Archived Nov 07, 2019
One ASX listed clinical stage oncology company is developing novel targeted cancer therapeutics for both humans and animals.
Next Investors Archived Oct 24, 2019
The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.
Next Investors Archived Oct 02, 2019
Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).
Get expert stock analysis direct in your inbox
Next Investors Archived Aug 14, 2019
MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion dollars and growing at 7% annually.
Next Investors Archived Jul 25, 2019
Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.
Next Investors Archived Jul 02, 2019
Who is the ASX company with transforming qualities that could completely disrupt the cannabis and CBD markets?
Next Investors Archived May 14, 2019
What if there was a cost effective way for patients to assess their cancer risk and seek treatment? There is. Genetic Technologies (ASX:GTG; NASDAQ:GENE).
Next Investors Archived Apr 08, 2019
Genetic Technologies (ASX:GTG) is a provider of world-leading genetic risk assessment test products.
Join Our Mailing List
